What drove the after-hours move in 4891.T stock today?

The after-hours drop followed the company's earnings announcement on 20 Jan 2026 and clinical updates. Volume of **368,300.00** shares rose above average, indicating active repositioning around trial news and guidance.

What is Meyka AI's view on 4891.T stock valuation?

Meyka AI assigns a **62.14** score (B, HOLD) to 4891.T stock. The model highlights strong cash buffers but weak profitability, giving a cautious hold stance until clinical catalysts materialise.

What are realistic price targets for 4891.T stock?

Scenario targets: conservative **¥120.00**, base **¥170.00**, optimistic **¥250.00**. Targets depend on clinical readouts, partner deals, and dilution risk for 4891.T stock.

How should investors monitor 4891.T stock moving forward?

Track clinical milestones for TMS-007, filings, news on partnerships, and trading volume. Monitor EPS **-15.64**, cash per share **¥67.81**, and Meyka AI updates for model revisions to 4891.T stock.

JP Stocks

TMS (4891.T, JPX) drops 4.46% after earnings on 20 Jan 2026: what to watch

ByHuzaifa Zahoor January 20, 2026January 20, 2026

TMS Co., Ltd. (4891.T) moved lower in after-hours trading, closing at ¥150.00, down ¥7.00 (-4.46%) after its earnings event on 20 Jan 2026. The market reaction follows an update tied to clinical progress and results timing. Volume rose to 368,300.00 shares, above the average of 302,742.00, signalling active repositioning. We summarise the earnings takeaways, valuation, technicals and near-term catalysts for the JPX-listed biotech.